East Asia Cell & Gene Therapy Tracker
Explore meaningful data coverage for 1000+ cell & gene therapy pipelines from around 250 Biopharma, Big Pharma, CMOs, and Research/Academic Institutes in the East Asia Region
Access comprehensive, validated data in a user-friendly manner. It's all here in a single click!
0
Cell and Gene Therapy Pipelines
0
Biopharma, Big Pharma, CMOs, and Research/Academic Institutes
0
Key Manufacturing Parameters
0
Key Pipeline Parameters
Tracker Highlights
Competitive Assessment
This tracker provides an in-depth overview of the upcoming competition in the cell & gene therapy market of East-Asian countries.
Through this tracker IMAPAC aims to assist organizations to keep track of their competitors, identify any opportunities for collaboration or investments for development or manufacturing of cell & gene therapies and support key strategic decisions making for the business.
Key Manufacturing Parameters
22+ parameters including facility centers, facility size, facility investment, production capacity, types of products manufactured in the facility, key features of the facility, operation scale, process technology, regulatory approvals & certifications, expansion plans and other vital information.
Key Pipeline Parameters
More than 20 parameters such as company overview, current cell & gene therapy products in pipeline, product’s stage of development, product by therapy type, autologous or allogenic therapies, disease or indication, target for each product candidate, route of administration, and technology employed in product’s development.
Key Companies Covered
JW Therapeutics, Hrain Biotechnology, GenomeFrontier Therapeutics, Takara Bio, Medipost, 3S Bio, MIimmune, Taiwan Biotherapeutics and other top cell & gene therapy companies in the region.
Countries Coverage
Tracker includes China, Japan, South Korea, Hong Kong and Taiwan among others, from discovery to commercialization in a single platform.
